Research
Hormonal
Pharmacological weight loss agents (e.g., GLP-1 agonists, Orlistat) are second-line treatments for OHS, used when lifestyle changes fail, but their efficacy is generally lower than bariatric surgery and they require careful monitoring for adverse effects.
If diet and exercise aren't enough, weight loss drugs can help. They are a second step, not a replacement for lifestyle changes. You must try them for 3 months; if you don't lose at least 5% of your body weight, stop and try a different approach or consider surgery.
ModerateQualifiesMEDIUM confidence
El tratamiento farmacológico para la obesidad debe usarse como segundo peldaño después de cambios en el estilo de vida (dieta equilibrada e incremento de la actividad física).
Why this rating
Based on a review of various drugs (Table 1) citing Katz et al., 2019, showing variable weight loss percentages.
Source
Revisión del tratamiento del síndrome obesidad hipoventilación
Mariara Calderón-Alcalá et al. · Revista de Patología Respiratoria · 2023
DOI 10.24875/rpr.22000027
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Non-invasive mechanical ventilation (NIV) is superior to Continuous Positive Airway Pressure (CPAP) for treating Obesity Hypoventilation Syndrome (OHS) in patients without severe Obstructive Sleep Apnea (OSA), as CPAP fails to adequately correct daytime hypercapnia in this subgroup.Good
- Bariatric surgery is the most effective intervention for sustained weight loss in Obesity Hypoventilation Syndrome, with gastric bypass being the most effective procedure for weight reduction, though it carries higher complication risks.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →